Current Status of Gene Therapy for Inherited Lung Diseases

Annual Review of Physiology

Volumn 65, Issue , 2003, Pages 585-612

  Driskell, Ryan A ^a   Engelhardt, John F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

1 antitrypsin deficiency; AAV; Adenovirus; Airway epithelium; Cystic fibrosis; Lung; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; LIPOSOME; PARVOVIRUS VECTOR; PLASMID DNA; RECOMBINANT DNA; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTHRALGIA; CELL POLARITY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG MEGADOSE; FEVER; GENE DELETION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMORAL IMMUNITY; INFECTION SENSITIVITY; LUNG FLUID; MYALGIA; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT MUCOSA; REVIEW; SIGNAL TRANSDUCTION; SPLICEOSOME; STEM CELL; TRANS SPLICING; TRANSGENE; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; GENE VECTOR; GENETICS; METHODOLOGY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; CYSTIC FIBROSIS; GENE THERAPY; GENETIC VECTORS; HUMANS;

EID: 0038311930     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.65.092101.142426     Document Type: Review

References (143)

1. Lewin AS, Hauswirth WW. 2001. Ribozyme gene therapy: applications for molecular medicine. Trends Mol. Med. 7:221-28
2. Richardson PD, Augustin LB, Kren BT, Steer CJ. 2002. Gene repair and transposon-mediated gene therapy. Stem Cells 20:105-18
3. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL, Sly WS, Valle D. 1995. Cystic fibrosis. In The Metabolic Basis of Inherited Disease, ed. CL Scriver, AL Beaudet, WS Sly, D Valle, pp. 3799-876. New York: McGraw-Hill
4. Guggino WB. 1999. Cystic fibrosis and the salt controversy. Cell 96:607-10
5. Jiang Q, Engelhardt JF. 1998. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Eur. J. Hum. Gen. 6:12-31
6. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, et al. 1992. An animal model for cystic fibrosis made by gene targeting. Science 257:1083-88
7. van Steenbergen W 1993. Alpha 1-antitrypsin deficiency: an overview. Acta Clin. Belg.48:171-89
8. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, et al. 1991. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252:431-34
9. Canonico AE, Conary JT, Meyrick BO, Brigham KL. 1994. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am. J. Respir. Cell Mol. Biol. 10:24-29
10. Kay MA, Li Q, Liu TJ, Leland F, Toman C, et al. 1992. Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum. Gene Ther. 3:641-47
11. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, et al. 1998. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 95:14384-88
12. Graham FL, Prevec L. 1995. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:207-20
13. Kovesdi I, Brough DE, Bruder JT, Wickham TJ. 1997. Adenoviral vectors for gene transfer. Curr. Opin. Biotechnol. 8:583-89
14. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, et al. 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-55
15. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-69
16. Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN, et al. 1994. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 371:802-6
17. Engelhardt JF, Yang Y, Stratford-Perricaudet LD, Allen ED, Kozarsky K, et al. 1993. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat. Genet. 4:27-34
18. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, et al. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-23
19. Walters RW, Grunst T, Bergelson JM, Finberg RW, Welsh MJ, Zabner J. 1999. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem. 274:10219-26
20. Greber UF, Willetts M, Webster P, Helenius A. 1993. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75:477-86
21. Goldman MJ, Wilson JM. 1995. Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J. Virol. 69:5951-58
22. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. 1998. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J. Virol. 72:6014-23
23. Yang Y, Li Q, Ertl HC, Wilson JM. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-15
24. Yeh P, Perricaudet M. 1997. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 11:615-23
25. Engelhardt JF, Litzky L, Wilson JM. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5:1217-29
26. Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, et al. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with El, E1/E2A, or E1/E4 deleted. J. Virol. 72:2022-32
27. Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan M, et al. 1999. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J. Virol. 73:6048-55
28. Engelhardt JF, Ye X, Doranz B, Wilson JM. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196-200
29. Zhou H, Pastore L, Beaud L, et al. 2002. Helper-dependent adenoviral vectors. Methods Enzymol. 346:177-98
30. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, et al. 1998. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum. Gene Ther. 9:2709-16
31. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, et al. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18:180-83
32. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22
33. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93:13565-70
34. Ng P, Beauchamp C, Evelegh C, Parks R, Graham FL. 2001. Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol. Ther. 3:809-15
35. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM. 1996. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:6370-77
36. Yang Y, Trinchieri G, Wilson JM. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1:890-93
37. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, et al. 2002. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 13:163-75
38. Cichon G, Boeckh-Herwig S, Schmidt HH, Wehnes E, Muller T, et al. 2001. Complement activation by recombinant adenoviruses. Gene Ther. 8:1794-800
39. Samulski RJ, Chang LS, Shenk T. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63:3822-28
40. 39a. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99: 11854-59
41. Berns KI. 1990. Parvovirus replication. Microbiol. Rev. 54:316-29
42. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, et al. 1990. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87:2211-15
43. Kearns WG, Afione SA, Fulmer SB, Pang MC, Erikson D, et al. 1996. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Ther. 3:748-55
44. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-45
45. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. 2001. Adeno-associated virus serotype 4 (aav4) and aav5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75:6884-93
46. Summerford C, Bartlett JS, Samulski RJ. 1999. Alphavbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82
47. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77
48. Walters RW, Duan D, Engelhardt JF, Welsh MJ. 2000. Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer to airway epithelia in vitro and in vivo. J. Virol. 74:535-40
49. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. 2000. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105:1573-87
50. Weiss DJ, Bonneau L, Allen JM, Miller AD, Halbert CL. 2000. Perfluorochemical liquid enhances adeno-associated virus-mediated transgene expression in lungs. Mol. Ther. 2:624-30
51. Auricchio A, O'Connor E, Weiner D, Gao G, Hildinger M, et al. 2002. Non-invasive gene transfer to lung for systemic delivery of therapeutic proteins. J. Clin. Invest. 110:499-504
52. Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE, et al. 1996. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 3:658-68
53. Rubenstein RC, McVeigh U, Flotte TR, Guggino WB, Zeitlin PL. 1997. CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector. Gene Ther. 4:384-92
54. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. 1997. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J. Virol. 71:5932-41
55. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. 2000. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74:1524-32
56. Halbert CL, Allen JM, Miller AD. 2001. Adeno-associated virus type 6 (aav6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of aav2 vectors. J. Virol. 75:6615-24
57. Duan D, Yue Y, Yan Z, McCray PB, Engelhardt JF. 1998. Polarity influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epithelia. Hum. Gene Ther. 9:2761-76
58. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, et al. 2000. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74:3852-58
59. Hernandez YJ, Wang J, Rearns WG, Loiler S, Poirier A, Flotte TR. 1999. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73:8549-58
60. Somia N, Verma IM. 2000. Gene therapy: trials and tribulations. Nat. Rev. Genet. 1:91-99
61. Kay MA, Glorioso JC, Naldini L. 2001. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7:33-40
62. Zhang Y, Chirmule N, Gao G, Wilson J. 2000. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J. Virol. 74:8003-10
63. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, et al. 2000. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74:2420-25
64. Haibert CL, Standaert TA, Wilson CB, Miller AD. 1998. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72:9795-805
65. Rutledge EA, Halbert CL, Russell DW. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72:309-19
66. Beck SE, Jones LA, Chesnut K, Walsh SM, Reynolds TC, et al. 1999. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J. Virol. 73:9446-55
67. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. 2002. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol. 76:2043-53
68. Summerford C, Samulski RJ. 1999. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat. Med. 5:587-88
69. Duan D, Yue Y, Yan Z, Engelhardt JF. 2000. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 6:595-98
70. Yan Z, Zhang Y, Duan D, Engelhardt JF. 2000. From the cover: trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA 97:6716-21
71. Sun L, Li J, Xiao X. 2000. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6:599-602
72. Nakai H, Storm TA, Kay MA. 2000. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 18:521-32
73. Duan D, Sehgal A, Yao J, Engelhardt JF. 1998. Lef1 transcription factor expression defines airway progenitor cell targets for in utero gene therapy of submucosal gland in cystic tibrosis. Am. J. Respir. Cell Mol. Biol. 18:750-58
74. Naldini L BU, Gallay P, Ory D, Mulligan R, Gage FH, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-67
75. Goldman MJ, Lee PS, Yang JS, Wilson JM. 1997. Lentiviral vectors for gene therapy of cystic fibrosis. Hum. Gene Ther. 8:2261-68
76. Wang GSV, Zabner J, Keshavjee S, Johnston JC, Sauter SL, et al. 1999. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin. Invest. 104:R55-62
77. Coil DA, Strickler JH, Rai SK, Miller AD. 2001. Jaagsiekte sheep retrovirus Env protein stabilizes retrovirus vectors against inactivation by lung surfactant, centrifugation, and freeze-thaw cycling. J. Virol. 75:8864-67
78. Tan Y, Li S, Pitt BR, Huang L. 1999. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Ther. 10:2153-61
79. Lee ER, Marshall J, Siegel CS, Jiang C, Yew NS, et al. 1996. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7:1701-17
80. Felgner PL. 1996. Improvements in cationic liposomes for in vivo gene transfer. Hum. Gene Ther. 7:1791-93
81. Matsui H, Johnson LG, Randell SH, Boucher RC. 1997. Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells. J. Biol. Chem. 272:1117-26
82. Alton EW, Middleton PG, Caplen NJ, Smith SN, Steel DM, et al. 1993. Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice Nat. Genet. 5:135-42. Erratum. Nat. Genet. 1993. 5:312
83. Hyde SC, Gill DR, Higgins CF, Trezise AE, MacVinish LJ, et al. 1993. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362:250-55
84. Zhang Y, Jiang Q, Dudus L, Yankaskas JR, Engelhardt JF. 1998. Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways. Hum. Gene Ther. 9:635-48
85. Chadwick SL, Kingston HD, Stern M, Cook RM, O'Connor BJ, et al. 1997. Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther. 4:937-42
86. + conductance in cystic fibrosis. Pflügers Arch. 431:1-9
87. Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, et al. 1992. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat. Genet. 2:240-48
88. Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, Wilson JM. 1994. Expression of the cystic fibrosis gene in adult human lung. J. Clin. Invest. 93:737-49
89. Jiang C, Finkbeiner WE, Widdicombe JH, McCray PB Jr, Miller SS. 1993. Altered fluid transport across airway epithelium in cystic fibrosis. Science 262:424-27
90. Smith JJ, Karp PH, Welsh MJ. 1994. Defective fluid transport by cystic fibrosis airway epithelia. J. Clin. Invest. 93:1307-11
91. Imler JL, Dupuit F, Chartier C, Accart N, Dieterle A, et al. 1996. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther. 3:49-58
92. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, et al. 2002. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA transsplicing. Nat. Biotechnol. 20:47-52
93. Basbaum CB, Jany B, Finkbeiner WE. 1990. The serous cell. Annu. Rev. Physiol. 52:97-113
94. Ferkol T, Perales JC, Eckman E, Kaetzel CS, Hanson RW, Davis PB. 1995. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 95:493-502
95. Engelhardt JF, Schlossberg H, Yankaskas JR, Dudus L. 1995. Progenitor cells of the adult human airway involved in submucosal gland development. Development 121:2031-46
96. Chu CS, Trapnell BC, Curristin SM, Cutting GR, Crystal RG. 1992. Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J. Clin. Invest. 90:785-90
97. Trapnell BC, Chu CS, Paakko PK, Banks TC, Yoshimura K, et al. 1991. Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc. Natl. Acad. Sci. USA 88:6565-69
98. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. 1992. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2:21-25
99. Duan D, Zhang Y, Engelhardt JF. 1998. Gene delivery to the airway. In Current Protocols in Human Genetics, ed. NC Dracopoli, JL Haines, BR Korf, DT Moir, CC Morton, et al, pp. 1391-34. New York: Wiley & Sons
100. Engelhardt JF. 2001. Stem cell niches in the mouse airway. Am. J. Respir. Cell Mol. Biol. 24:649-52
101. Borthwick DW, Shahbazian M, Krantz QT, Dorin JR, Randell SH. 2001. Evidence for stem-cell niches in the tracheal epithelium. Am. J. Respir. Cell Mol. Biol. 24:662-70
102. Reynolds SD, Giangreco A, Power JH, Stripp BR. 2000. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am. J. Pathol. 156:269-78
103. Pitt BR, Schwarz MA, Pilewski JM, Nakayama D, Mueller GM, et al. 1995. Retrovirus-mediated gene transfer in lungs of living fetal sheep. Gene Ther. 2:344-50
104. Stern M, Caplen NJ, Browning JE, Griesenbach U, Sorgi F, et al. 1998. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther. 5:91-98
105. Perricone MA, Rees DD, Sacks CR, Smith KA, Kaplan JM, St George JA. 2000. Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells. Hum. Gene Ther. 11:1997-2008
106. Kitson C, Angel B, Judd D, Rothery S, Severs NJ, et al. 1999. The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther. 6:534-46
107. Virella-Lowell I, Poirier A, Chesnut KA, Brantly M, Flotte TR. 2000. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther. 7:1783-89
108. Crystal RG. 1997. The Lung: Scientific Foundations. Philadelphia: Lippincott-Raven
109. Sheils CA, Kas J, Travassos W, Allen PG, Janmey PA, et al. 1996. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am. J. Pathol. 148:919-27
110. Bastian A, Schafer H. 2001. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul. Pept. 101:157-61
111. Zabner J, Freimuth P, Puga A, Fabrega A, Welsh MJ. 1997. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J. Clin. Invest. 100:1144-49
112. Wang G, Davidson BL, Melchert P, van Es HHG, Bodner M, et al. 1998. Efficient gene transfer to differentiated human airway epithelia with recombinant amphotropic and xenotropic retroviruses. J. Virol. 72:9818-26
113. Chu Q, St George JA, Lukason M, Cheng SH, Scheule RK, Eastman SJ. 2001. EGTA enhancement of adenovirus-mediated gene transfer to mouse tracheal epithelium in vivo. Hum. Gene Ther. 12:455-67
114. Wang G, Zabner J, Deering C, Launspach J, Shao J, et al. 2000. Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am. J. Respir. Cell Mol. Biol. 22:129-38
115. Chu Q, Tousignant JD, Fang S, Jiang C, Chen LH, et al. 1999. Binding and uptake of cationic lipid:pDNA complexes by polarized airway epithelial cells. Hum. Gene Ther. 10:25-36
116. Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. 1998. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J. Clin. Invest. 102:184-93
117. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. 2000. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74:992-96
118. Dong JY, Fan PD, Frizzell RA. 1996. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7:2101-12
119. Wang D, Fischer H, Zhang L, Fan P, Ding RX, Dong J. 1999. Efficient CFTR expression from AAV vectors packaged with promoters - the second generation. Gene Ther. 6:667-75
120. Flotte TR, Afione SA, Solow R, Drumm ML, Markakis D, et al. 1993. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268:3781-90
121. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, et al. 2001. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12:1907-16
122. Zhang L, Wang D, Fischer H, Fan PD, Widdicombe JH, et al. 1998. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc. Natl. Acad. Sci. USA 95:10158-63
123. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. 1999. Concatamerization of adeno-associated viral circular genomes occurs through intermolecular recombination. J Virol. 73:9468-77
124. Duan D, Yan Z, Yue Y, Engelhardt JF. 1999. Structural analysis of adeno-associated virus transduction intermediates. Virology 261:8-14
125. Duan D, Yue Y, Engelhardt JF. 2001. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4:383-91
126. McCarty DM, Monahan PE, Samulski RJ. 2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8:1248-54
127. Mansfield SG, Kole J, Puttaraju M, Yang CC, Garcia-Blanco MA, et al. 2000. Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther. 7:1885-95
128. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207-16
129. Hay JG, McElvaney NG, Herena J, Crystal RG. 1995. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum. Gene Ther. 6:1487-96
130. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, et al. 1996. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 97:1504-11
131. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, et al. 1995. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:823-31
132. Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, et al. 1999. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum. Gene Ther. 10:2973-85
133. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, et al. 1997. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum. Gene Ther. 8:15-25
134. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, et al. 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8:42-51
135. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, et al. 1999. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104:1245-55
136. Perricone MA, Morris JE, Pavelka K, Plog MS, O'Sullivan BP, et al. 2001. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum. Gene Ther. 12:1383-94
137. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, et al. 1995. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1:39-46. Erratum. Nat. Med. 1995 1(3):272
138. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, et al. 1997. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4:199-209
139. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, et al. 1997. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4:210-18
140. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, et al. 1999. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353:947-54
141. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, et al. 2001. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum. Gene Ther. 12:751-61
142. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, et al. 1998. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351:1702-3
143. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, et al. 1999. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109:266-74